Updates

• 14 October 2022

  PAXLOVID Now Available Through Global Fund Support

  The new COVID-19 oral antiviral medicine nirmatrelvir/ritonavir, better known as PAXLOVID, is now available to be procured through Global Fund support.
• 14 October 2022

  CCM Evolution: New Integrated Performance Framework

  The Global Fund is introducing a new Integrated Performance Framework for Country Coordination Mechanisms (CCMs), Principal Recipients (PRs) and Local Fund Agents (LFAs) to to strengthen CCMs annual performance and eligibility against criteria 3-6 in...
• 14 October 2022

  CCM Evolution eLearning Course

  The Global Fund has launched a new eLearning course for Country Coordination Mechanisms (CCMs), Principal Recipients (PRs) and Local Fund Agents (LFAs) to strengthen program implementation. The course consists of four modules corresponding to the CCM...
• 02 September 2022

  Operational Update: Fight for What Counts
• 29 July 2022

  Updated Application Materials for the 2023-2025 Funding Cycle

  Application materials for the Global Fund’s 2023-2025 funding cycle are now available on our website, after going through extensive internal and external consultations and alignment with the new 2023-2028 Global Fund Strategy.
• 20 July 2022

  Urgent C19RM Reinvestments

  Due to the changing nature of the COVID-19 pandemic and contributing factors, the Global Fund will be supporting implementing countries to urgently reinvest COVID-19 Response Mechanism (C19RM) funds, where the initial intent of these investments no l...